A recently announced partnership between Nusano (West Valley City, UT) and dGenThera (Durham, NC) secures At-211 supply, advancing targeted alpha therapies for precision cancer treatment, leveraging innovative theranostics and scalable isotope production.
Durham, N.C. and West Valley City, Utah - June 19, 2025
In a transformative step for precision oncology, Nusano, a physics company redefining radioisotope production and dGenThera, Inc., a trailblazer in theranostic molecular pairs, have signed a letter of intent to secure a reliable supply of high-purity astatine-211 (At-211) for dGenThera’s groundbreaking targeted alpha therapies (TATs). This partnership marks a pivotal moment in the fight against cancer, unlocking the potential of At-211, an alpha-emitting isotope poised to redefine next-generation cancer treatments.
A Game-Changer for Targeted Cancer Therapies
At-211 is emerging as the gold standard for targeted radiotherapeutics due to its unique properties: high-energy, short-range alpha emissions that destroy cancer cells with pinpoint accuracy while sparing healthy tissue. Unlike other alpha emitters like actinium-225 or lead-212, At-211 produces no harmful daughter isotopes, and its 7.2-hour half-life is ideal for systemic delivery and tumor targeting. Its ability to cross the blood-brain barrier also positions it as a critical tool for treating primary brain cancers and metastases, addressing some of the most challenging oncology indications.
“This partnership with Nusano is a game-changer for dGenThera and the broader field of targeted alpha therapy,” said Louis Metzger, Co-founder and CEO of dGenThera. “Securing a stable supply of At-211 empowers us to accelerate our preclinical studies, initiate first-in-human trials, and ultimately bring transformative therapies to patients. Nusano’s cutting-edge production capabilities are unlocking At-211’s potential to become the cornerstone of ‘targeted radiotherapy 2.0’.”
Nusano’s Breakthrough Technology Addresses Supply Challenges
The widespread adoption of At-211 has long been hindered by limited production capacity. Nusano’s state-of-the-art facility nearing completion in West Valley City, Utah changes that, leveraging proprietary accelerator technology to produce At-211 at unprecedented scale. With an alpha beam ten times more powerful than all comparable systems combined, Nusano’s facility is poised increase global At-211 supply by 100-fold, enabling reliable distribution across the U.S. and beyond.
“Nusano is committed to empowering innovators like dGenThera with the isotope supplies needed to develop life-saving radiotherapeutics,” said Chris Lowe, CEO of Nusano. “This agreement is a testament to our mission of advancing precision medicine by making At-211 widely available for clinical and commercial use.”
dGenThera’s Vision: Precision Theranostics at Scale
dGenThera’s proprietary platform of theranostic molecular pairs sets a new standard for image-guided radiotherapy. By designing therapeutic molecules (using At-211 or iodine-131) that are nearly identical to their diagnostic counterparts (using fluorine-18), dGenThera ensures seamless integration into existing nuclear medicine workflows. This approach eliminates the stability and safety concerns associated with chelated metal emitters, simplifies regulatory pathways, and enables true precision medicine.
“Our theranostic pairs are designed to make At-211-based therapies as accessible as F-18 PET imaging,” said Anthony Casarez, Ph.D., Co-founder and Chief Scientific Officer of dGenThera. “This partnership with Nusano ensures we can scale our pipeline from bench to bedside, delivering targeted therapies that are both highly effective and safe for patients.”
A Partnership with Global Implications
This collaboration positions dGenThera and Nusano at the forefront of the radiotherapeutics revolution. By combining dGenThera’s innovative molecular designs with Nusano’s unparalleled isotope production, the partnership paves the way for rapid clinical development and eventual commercialization of At-211-based therapies. With applications across multiple high-unmet-need cancer indications, this alliance promises to bring hope to patients battling some of the most aggressive forms of cancer.
Visit nusano.com and jGenThera.com for more information.
